Scholarlink

<p>Host factors that are involved in modulating cellular vesicular trafficking of virus progeny could be potential antiviral drug targets. ADP-ribosylation factors (ARFs) are GTPases that regulate intracellular vesicular transport upon GTP binding. Here we demonstrate that genetic depletion of ARF4 suppresses viral infection by multiple pathogenic RNA viruses including Zika virus (ZIKV), influenza A virus (IAV) and SARS-CoV-2. Viral infection leads to ARF4 activation and virus production is rescued upon complementation with active ARF4, but not with inactive mutants. Mechanistically, ARF4 deletion disrupts translocation of virus progeny into the Golgi complex and redirects them for lysosomal degradation, thereby blocking virus release. More importantly, peptides targeting ARF4 show therapeutic efficacy against ZIKV and IAV challenge in mice by inhibiting ARF4 activation. Our findings highlight the role of ARF4 during viral infection and its potential as a broad-spectrum antiviral target for further development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ARF4-mediated intracellular transport as a broad-spectrum antiviral target

  • 期刊论文

  • 发表日期：

    2025年2月19日

查看全文
  • Ming-Yuan Li,
  • Kao Deng,
  • Xiao-He Cheng,
  • Lewis Yu-Lam Siu,
  • Zhuo-Ran Gao,
  • Trupti Shivaprasad Naik,
  • Viktoriya G. Stancheva,
  • Peter Pak-Hang Cheung,
  • Qi-Wen Teo,
  • Sophie W. van Leur,
  • Ho-Him Wong,
  • Yun Lan,
  • Tommy Tsan-Yuk Lam,
  • Meng-Xu Sun,
  • Na-Na Zhang,
  • Yue Zhang,
  • Tian-Shu Cao,
  • Fan Yang,
  • Yong-Qiang Deng,
  • Sumana Sanyal,
  • Cheng-Feng Qin

摘要

Host factors that are involved in modulating cellular vesicular trafficking of virus progeny could be potential antiviral drug targets. ADP-ribosylation factors (ARFs) are GTPases that regulate intracellular vesicular transport upon GTP binding. Here we demonstrate that genetic depletion of ARF4 suppresses viral infection by multiple pathogenic RNA viruses including Zika virus (ZIKV), influenza A virus (IAV) and SARS-CoV-2. Viral infection leads to ARF4 activation and virus production is rescued upon complementation with active ARF4, but not with inactive mutants. Mechanistically, ARF4 deletion disrupts translocation of virus progeny into the Golgi complex and redirects them for lysosomal degradation, thereby blocking virus release. More importantly, peptides targeting ARF4 show therapeutic efficacy against ZIKV and IAV challenge in mice by inhibiting ARF4 activation. Our findings highlight the role of ARF4 during viral infection and its potential as a broad-spectrum antiviral target for further development.